Sentence examples for while discontinuing from inspiring English sources

Among individuals < daily heroin injection, not being on MMT was associated with ART discontinuation (AHR = 1.30, 95%% CI: 1.05 1.60) while discontinuing MMT was not associated with ART discontinuation (AHR = 1.45, 95%% CI: 0.90 2.34).

They point out that department stores have moved aggressively into apparel in recent years because of higher markups while discontinuing some of their home furnishings departments.

As patients learn about treatments, they continue effective ones while discontinuing ineffective ones.

Dole says that each year it introduces new blends, such as the baby spinach salad it will introduce this fall, while discontinuing slower-moving items so the number of items on supermarket shelves remains fairly constant.

In July 2012, weekly Paclitaxel-Carboplatin therapy was added to Bevacizumab while discontinuing Tamoxifen, due to multi-organ progression.

Why the majority of players would adopt head and face protection while discontinuing hand protection use cannot be addressed in this cross-sectional study.

To be clear, while Adero is discontinuing the TrackR, the company has confirmed that it will continue to support those that are in the market (for the time being).

While Google is discontinuing Play for Education, teachers and administrators can still use Google's and its partners' other device management services to push educational apps from the Play Store to tablets, as well.

In patients with inactive disease at baseline (category 3), success (or efficacy) of treatment was assessed by the proportion of patients who maintained quiescent uveitis throughout the 6-month period of the study while tapering or discontinuing their previous CS therapy.

As far as we are aware, the U-TURN study is the first study to investigate if lifestyle intervention is effective in maintaining glycaemic control while aiming at discontinuing pharmacological care in patients with T2D.

The percentage of participants starting a study drug after baseline ranged from 2% (180/7380) for metformin to 13% (517/3986) for RAS blockers, while the proportion discontinuing a study drug present at baseline ranged from 8% for statins (386/4553) and β blockers (316/3987) to 18% (208/1148) for clopidogrel.